The physical health burden of endometriosis can cause infertility and lead to hysterectomy for up to 20% of affected women. However, only one new treatment was approved for the disease in the past decade. Endometriosis' impact reverberates through the healthcare system, economy, and society as millions of women suffer and the direct and indirect costs continue to mount. To address this unmet medical need, FimmCyte has engineered a first-in-class, disease-modifying treatment that has shown efficacy in eliminating endometriosis in the lab and animal models. FimmCyte will use the CHF 150,000 Venture Kick award to advance their lead candidate through preclinical regulatory requirements to pave the way for the first-in-human trial within the next few years.FimmCyte wins CHF 150'000 to advance their non-hormonal, disease-modifying treatment for endometriosis.